By integrative practitioner staff
Handspring is growing its workforce, partnerships, and reach to provide virtual mental health treatment to youth and families; Supply6 plans to enhance its product innovations, clinical research and digital experience; And more.
$73.8 million: Series B for a SARM1 inhibitor to treat amyotrophic lateral sclerosis
Nura Bio announced the completion of a $73.8 million Series B financing and the development of two clinical-stage SARM1 inhibitor programs. Proceeds will fund development of Nura Bio’s clinical pipeline, including a Phase 1b/2a study of NB-4746, an oral, brain-penetrating SARM1 inhibitor, which recently began dosing in amyotrophic lateral sclerosis (ALS) patients. NB-4746 has been shown to prevent SARM1-induced axonal degeneration, providing neuroprotection in multiple preclinical models of nerve injury and disease, including amyotrophic lateral sclerosis. In a phase 1 study in healthy volunteers, NB-4746 demonstrated a favorable safety profile and achieved target plasma and cerebrospinal fluid exposure levels. press release.
$19 million: Series B for youth behavioral health model
Handspring has secured $19 million in Series B funding to grow its physician workforce, expand value-based care partnerships with payers, and expand its geographic reach. The health organization offers a virtual mental health clinic for youth and families, specifically designed for evidence-based care, training and ongoing support for clinicians. Handspring doctors treat children and teens ages 8 to 17, as well as young adults ages 18 to 26. Doctors are trained to treat anxiety, depression, OCD, ADHD, trauma, and other mental health challenges. The model of care also includes ongoing training and support for parents who are seen as an essential part of the treatment process. This support includes parent training sessions using Behavioral Parent Training (BPT). press release.
$17 million: Series B to expand mental health care
Vanna Health has raised $17 million in a Series B funding round. The company will use the capital to expand its clinical footprint, enhance its technology infrastructure, and bring its care model to new markets. The company’s new mission is to steer the company toward new automation and predictive analytics capabilities to inform real-time care, to which some of the new capital will be allocated. press release.
$7M: Series A for AI-powered preventive health platform
SuperLiving has secured $7 million in a Series A funding round to advance its AI-powered preventive health platform. The company provides a personalized health ecosystem that serves users with an AI companion capable of tracking lifestyle metrics and providing personalized health recommendations. SuperLiving plans to use the fresh capital to enhance its AI infrastructure, expand the regional language content ecosystem, and accelerate product development. press release.
$5 million: Financing supplementary expansion
Supply6 has raised $5 million in a funding round that will be used for product innovation, clinical research, supply chain capabilities, digital experience, and expansion across direct-to-consumer, marketplaces and express commerce channels. Supply6 offers daily supplements across the vitamin, hydration, and fiber categories. Its flagship product, Supply6 360, combines more than 63 ingredients, including probiotics, micronutrients, and adaptogens. press release.
